**How to request feedback on reviews in production**

The Associate Editor in each network can provide feedback on reviews when requested by individual Cochrane Review Groups (CRGs). There are various scenarios when it may be appropriate to contact your Associate Editor for review screening or other quick checks, as listed in Box 1. The aim of screening is primarily intended to help decide what sort of additional work might be needed before publication. Screening is carried out using a Triage Tool (see [Appendix 1](#_Appendix_1:_Triage)) that focuses on three separate aspects of the review: possible errors in the analysis of data, common issues in the interpretation of findings and information embedded in the Summary of Findings (SoF) table, and consistency of reporting in the abstract. However, other quick checks and feedback may be appropriate rather than providing a full screening report.

The process for review screening is detailed in Box 2, but please contact your [Associate Editor](https://community.cochrane.org/organizational-info/resources/resources-groups/crg-networks-portal/8-crg-networks) if you have any queries.

# Box 1: Possible scenarios for referral of reviews for screening

|  |
| --- |
| 1. **CRG referral for high priority reviews (screening report)**

If the review:* is a high priority (e.g. being completed for a guideline or is on the high priority reviews list) and the CRG would like further input;
* is high profile and may be controversial (awaiting final approval of guidance: “Identifying, managing and communicating high-priority, highly visible and high-risk reviews”)
* is accepted for Fast-Track (screening is compulsory part of the Fast-Tract editorial process, rather than a referral from the CRG);
* is subject to funding (such as an incentive award);
* is a candidate for enhanced dissemination (including a press release).
1. **Other CRG referrals (optional quick checks or screening report)**
* Methodological queries, concerns or uncertainty.
* Support for rejection.
* Complex methods and the CRG does not otherwise have access to appropriate methodological support (e.g. from the NIHR Complex Reviews Support Unit).
* Any potential conflict of interest of editorial staff e.g. if the Co-ordinating Editor and/or Managing Editor is an author. Sign-off for publication to be provided by Network Senior Editor.
* When multiple iterations have been made and an independent perspective is required (a “fresh pair of eyes”).
1. **External sources**
* Red flags from the abstract (stage E alert) identified by the Senior or Associate Editor or via the weekly Analysis of Review Group Output (ARGO) meeting held by UK Cochrane Centre.
* Occasional referrals from Copy Edit Support or via Cochrane Clinical Answers.
* Critical feedback, retracted studies or comments received after publication.
 |

# Box 2: Process for review screening

|  |
| --- |
| 1. When CRGs have identified the need for screening (see Box 1 for possible scenarios), they should contact the Associate Editor and Senior Editor for their Network as soon as possible. Any advance notice of upcoming reviews to be referred for screening, in particular that require a quick turnaround or are large, would be much appreciated. In most cases reviews will be referred for screening prior to copy edit, however it may be appropriate for the processes to be run in parallel.
2. Reviews can be referred for screening at any stage of the editorial process, and checks can be carried out on, but not limited to the:
	* Protocol;
	* Results and analysis;
	* Implementation of GRADE and Summary of findings tables;
	* Abstract and plain language summary;
	* Discussion & conclusions
3. Associate Editors will consult with other sources of advice as necessary, for example other Associate Editors, Senior Editors or the Methods Support Team (to be established during 2019).
4. Associate Editors will screen the review using the Triage Tool (see Appendix 1) and return a written report to the CRG.
5. Associate Editors will also specify whether they will need to rescreen the amended review before proceeding, or if they are happy for the CRG to check amendments are made.
6. Please note that turnaround time for a screening report will depend on the volume of queries received and the size of the review. An estimate of completion can be provided once a request is received.
 |

# Appendix 1: Triage Tool

|  |  |
| --- | --- |
| **Review title** |  |
| **Authors** |  |
| **CRG** |  |
| **Archie version no.** |  |

|  |  |  |
| --- | --- | --- |
| **IMPLEMENTATION OF PROTOCOL METHODS**  | **SUMMARY OF FINDINGS TABLE** | **ABSTRACT** |
| **Item**  | **Response** | **Item**  | **Response**  | **Item**  | **Response** |
| Appropriate eligibility decisions *Check protocol comparison generated from Archie and Differences between protocol & review for any changes to design of review (eligibility criteria, outcomes);**Check for exclusions based on reporting of data* |  | SoF table presents main outcomes (benefits & harms) for main comparison*Look at methods section for consistency of SoF table outcomes; Assess methods for using GRADE* |  | Title reflects review question |  |
| Research question (PICO) clear & rationale for review described |  |
| Appropriate risk of bias assessment*Check for omission of standard domains;* *inclusion of any non-standard domains is explained & justified;* *domains appear well understood (fit between explanation and domain, appropriate judgments)*  |  | PICO (including Settings) are accurate & informative |  | Search date <12 months from publication |  |
| Outcomes fully defined (i.e. time of measurement, scale of measurement, range of scores specified) |  | Characteristics of included studies summarised *Consider copying & summarising information presented under ‘Description of included studies’/Overall completeness & applicability’. Look for details in SoF table relating to settings & participants.*  |  |
| Analyses match with methods section *MDs/SMDs; fixed/random effects, subgroup analysis. Check protocol comparison and Differences between protocol & review to see what plans changed from protocol.* |  | Assumed & Corresponding risks included (where appropriate) |  | Findings for all important outcomes reported for main comparison(s), including information about harms *Check consistency with first SoF table & others as appropriate* |  |
| Data from non-standard designs (cluster, cross-over, etc.) appropriately incorporated where relevant *Check ‘Unit of analysis issues’ in methods/footnotes in forest plots/sensitivity analyses. Scan study characteristics to confirm unit of allocation & sample sizes if in doubt.* |  | GRADE ratings justified & adequately explained |  | Direction, magnitude & confidence intervals of effects clearly described where appropriate |  |
| Clear & accurate summary of narrative results (where appropriate) |  | Reporting results avoids emphasizing statistical significance to determine presence or absence of an effect |  |
| Quality ratings presented for narrative results (where appropriate) |  | GRADE ratings for outcomes reported in abstract |  |
| Multiple measurements from studies with more than one eligible comparator handled appropriately*Check for double counting of studies in Forest plot & adjustment of events/sample size in control groups* |  | Absolute effects used to illustrate the relative effects where appropriate |  |
| Outlying results acknowledged & explored appropriately *Consider how plausible the direction/size of effects are overall, explore data from studies with unusually large or discordant effects* |  |